Oral Anticoagulation and the Devil You Don't Know vs the Devil You Do: Safety of NOACs vs Warfarin

Size: px
Start display at page:

Download "Oral Anticoagulation and the Devil You Don't Know vs the Devil You Do: Safety of NOACs vs Warfarin"

Transcription

1 Oral Anticoagulation and the Devil You Don't Know vs the Devil You Do: Safety of NOACs vs Warfarin Charles V. Pollack, Jr., M.A., M.D., FACEP, FAAEM, FAHA, FCPP Professor and Chairman Department of Emergency Medicine Pennsylvania Hospital University of Pennsylvania Philadelphia

2 Disclosure of Significant Relationships with Relevant Commercial Interests Charles V. Pollack, Jr., MA, MD No promotional activities Consultant to Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, Pfizer, Durata, Luitpold Research support from Luitpold Pharmaceuticals, AstraZeneca

3 Oral Anticoagulation and the ED Initiate therapy for VTE (DVT and PE) Parenterally with unfractionated heparin, enoxaparin, dalteparin, fondaparinux, coupled with (and bridging to) warfarin Rivaroxaban (only FDA approved option to date, does not require bridging) Apixaban expected to be approved 2014, does not require bridging Dabigatran and edoxaban may be approved, do require bridging Initiate (or facilitate) anticoagulation for SPAF Mostly done by cardiologists or hospitalists Bridging not usually done Warfarin, rivaroxaban, apixaban, dabigatran Manage patients with ED presentations (including bleeding complications) who are being treated for VTE, on SPAF, or with mechanical valves, etc, with any of these agents

4 Evolving Approach to Anticoagulation Direct Xa Inhibitors Oral 2000s Direct thrombin Inhibitors Indirect Xa Inhibitors LMWH VKA Heparin Class of drug Courtesy F. Michota MD.

5 Inhibition of Vitamin K Dependent Coagulation Factors by Warfarin Intrinsic XII Extrinsic XI IX TF Protein C & S VIII Xa VII V II IIa Fibrinogen Fibrin Clot Weitz JI, et al. Chest. 2001;119(1 suppl):95s-107s; Gulseth MP, et al. Am J Health Syst Pharm. 2008;65(16):

6 Selective Factor Inhibition Novel Oral Anticoagulants Intrinsic XII Extrinsic XI IX TF Xa is an amplifica,on step Protein C & S VIII II Xa V IIa VII Rivaroxaban Apixaban Edoxaban Dabigatran (also inhibits clot- bound thrombin) Fibrinogen Fibrin Clot Blommel ML, et al. Am J Health-Syst Pharm. 2011;68: ; Gulseth MP, et al. Am J Health-Syst Pharm. 2008;65: ; Nutescu E. Am J Health-Syst Pharm. 2012;69: ; Palladino M, et al. Am J Hematol. 2012;87(suppl 1): ; Wittkowsky AK. Pharmacotherapy. 2011;31:

7 New Oral Anticoagulant Development Nonvalvular Atrial Fib and VTE In Development XARELTO (rivaroxaban) Bayer/JNJ QD/BID, fxa Inhibitor ORS 3Q11 AF 4Q11 DVT PE 4Q12 Pradaxa (dabigatran) Boehringer Ingelheim QD/BID, DT Inhibitor AF 3Q10 DVT PE App 4Q13 Eliquis (apixaban) BMS/Pfizer BID, fxa Inhibitor AF 4Q12 DVT PE App 4Q14 Lixiana (edoxaban) Daiichi Sankyo QD, fxa Inhibitor AF Antic 4Q14 DVT PE Antic 4Q14 Betrixaban Portola QD, fxa Inhibitor 7 Med Ill Antic 2Q16

8 NOACs in clinical trials SPAF, compared to warfarin: Dabigatran (150): superior efficacy all stroke, ischemic stroke; noninferior major bleed; superior all-cause mortality Rivaroxaban: noninferior efficacy all stroke, ischemic stroke; noninferior major bleed; noninferior all-cause mortality Apixaban: superior efficacy all stroke, noninferior ischemic stroke; superior major bleed; superior all-cause mortality All three had lower rates of intracranial bleeding compared to warfarin VTE treatment, compared to enox or UFH bridge to warfarin: Rivaroxaban: noninferior efficacy and safety Apixaban (not yet approved): noninferior efficacy, superior safety Dabigatran (not approved): noninferior efficacy and safety Edoxaban (not approved): noninferior efficacy, superior safety

9 Overview and Pharmacology Novel Oral Anticoagulants Apixaban 1-4 Dabigatran 1,5 Rivaroxaban 1,6 Drug class Direct factor Xa inhibitor Direct factor IIa inhibitor Direct factor Xa inhibitor Bioavailability 50% 3%-7% 80%-100% for 10 mg dose 66% for 20 mg dose Onset of anticoagulant effect Within 3 hours Within 2 hours Within 4 hours CYP metabolism 25% CYP3A4 No 30% CYP3A4, CYP2J2 Renal excretion 27% 80% 36% Half-life 12 hours hours 5-9 hours Dosage form Tablet Capsule Tablet Dosing frequency BID BID BID or once daily CYP = cytochrome P Wittkowsky AK. Pharmacotherapy. 2011;31: Zhang D, et al. Drug Metab and Disp. 2009;37: Eliquis (apixaban). Available at: curl=pages/medicines/human/medicines/002148/human_med_ jsp&mid=wc0b01ac058001d124; 4. Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company. December 2012; 5. Pradaxa (dabigatran etexilate mesylate) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc. November 2012; 6. Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; November 2012.

10 Safety Concerns with NOACs Conundrum # 1 Patients on NOACs do not require routine anticoagulation monitoring. Conundrum # 2 Warfarin is safer than the NOACs because it can be reversed. Question: What is the best ED strategy for managing oral anticoagulant-related hemorrhage or intracranial bleed?

11 Conundrum # 1: Monitoring NOACs When dosed properly by indication and renal function, routine monitoring not required for NOACs used in treating VTE or providing SPAF At times, especially in ED when evaluating bleeding or bleeding concern in patients taking a NOAC, measurement of anticoagulation activity is desirable Standard PT/INR and aptt measures will not quantitatively assess anticoagulation with NOACs

12 Role of Coagulation Testing a for NOACs Apixaban 1-3 Dabigatran 1,2 Rivaroxaban 1-3 Ecarin clotting time (ECT) NA 5.2x baseline NA Anti-Xa activity NR NA 22% with 5 mg 68% with 30 mg Thrombin time (TT) NA 27x baseline NA Prothrombin time (PT) 2,4 Range: There are no commercially available anti-xa assays calibrated for NOACs, only for UFH/LMWH Little effect at clinically relevant plasma concentration Range: INR 1.5x baseline 1.8x baseline NR Activated partial thrombo-plastin time (aptt) 1.2x baseline 2.3x baseline 1.8x baseline HepTest NA NA 2.8x baseline Preferred Test Anti-Xa, mptt, HepTest ECT b, TT Anti-Xa c, PT d a Useful for assessing: compliance, drug interactions, overdose, use in renal and/or hepatic impairment; NOT to be used routinely for dose adjustments; b not readily available; c can use same assay as enoxaparin; d reagent dependent NA = not applicable; NR = not reported; mptt = modified prothrombin time 1. Eriksson BI, et al. Clin Pharmacokinet. 2009;48:1-22; 2. Barrett YC, et al. Thromb Haemost. 2010;104: ; 3. Kubitza D, et al. Eur J Clin Pharmacol. 2005; 61: ; 4. van Ryn J, et al. Thromb Haemost. 2010;103:

13 Assessing Intensity of Anticoagulation Effects Drug Present Quantitative Test Sensitivity: PT vs aptt No or Limited Effect Apixaban/Rivaroxaban? Chromogenic anti-factor Xa High sensitive INR Chromogenic anti-factor Xa PT > aptt ECT, TT Thrombin time Dabigatran? Dilute thrombin time or chromogenic ECT aptt > PT (point-of-care INR > central lab) Lindhoff-Last E, et al. Ther Drug Monit. 2010;32: ; Lindahl TL, et al. Thromb Haemost. 2011;105: ; van Ryn J, et al. Am J Med. 2012;125: ; van Ryn J, et al. Thromb Haemost. 2010;103:

14 Conundrum # 2: Reversal of Warfarin It is inaccurate to refer to use of vitamin K as reversing warfarin-induced anticoagulation Use more accurate Anticoagulation with warfarin results from depletion of vitamin K-dependent clotting factors II, VII, IX, and X, and proteins C and S terminology: Administration of vitamin K allows liver to begin synthesizing these factors again REVERSE Endogenous repletion and correction of INR may take up to 24 h or longer, depending on patient s liver health and overall physiologic status If goal is hemostasis and not normal INR, exogenous repletion in addition to vitamin K must be provided RESUSCITATE AND REPLETE There is no analogue to Vitamin K treatment in patients taking NOACs Half-life of all NOACs significantly shorter than that of warfarin, so intensive support should be required for a shorter interval

15 Step 1: Resuscitate + Fresh-Frozen Plasma ABCs - Replete volume for BP (and, if needed, ICP) control - Type and cross-match - Stop interruptible blood loss (tamponade, endoscopy, interventional radiology) Decon - Consider activated charcoal - (dabigatran only) consider hemodialysis FFP 1 - Partially restores clotting factor levels - Blood typing required - Must be thawed at 30 o 37 o C for min prior to use - Dosing is 15 ml/kg (infusion 3 6 h), which is a large amount of colloid volume Special considerations: Potential for circulatory overload Small risk of: viral transmission, passive alloimmune thrombocytopenia, anaphylaxis, septicemia 1. Cervera A, et al. J Neurol. 2012;259:

16 Effects of Repletion Agents on Anticoagulant Activity in an Ex-Vivo Model Measured Effect on Thrombin Generation: AUC, Peak, Time to Peak, and Lag Time Nonspecific Reversal Agent rfviia: NovoSeven 0.5,1.5,3 ug/ml apcc: FEIBA 0.25,0.5,1,2 U/mL 4-factor PCC a : Kanokad 0.25,0.5,1 U/mL Conclusions: If immediate reversal is needed, currently no clear evidence for any reversal agent clinically FEIBA effective for rivaroxaban ex-vivo, but higher doses are associated with more thrombin generation; clinically may cause more thrombosis Marlu R, et al. Thromb Haemost. 2012;108: Not tested Not tested Not tested Apixaban Dabigatran 150 mg + (lag time) + (lag time) + (increased AUC) Rivaroxaban 20 mg + (lag time) +++ (AUC, peak, lag time, and time to peak) ++ (strongly corrected AUC, modest peak) a PCCs contain significant quantities of factors II, IX, and X; 4-factor PCCs (approved but not yet available in the US) also contain factor VII rfviia = recombinant activated clotting factor VII

17 4-Factor PCC now FDA-Approved Repletes II, VII, IX, and X, plus proteins C and S (VII lacking in 3-factor PCC) Lower volume infusion required than FFP, with ~25x the factor concentration To date, much more study in treating warfarin-related bleeding than NOACs Reduces INR faster than FFP Restores factor levels faster than FFP 7x faster infusion time than FFP 87% reduction in volume of infusion compared to FFP Similar safety profile to FFP Sarode R, et al. Circulation Aug 9. [Epub ahead of print].

18 Managing Bleeding in Patients Receiving Apixaban Apixaban No established way to reverse anticoagulant effect, which persists ~24h after last dose Because of high plasma protein binding, apixaban is not dialyzable Protamine sulfate and vitamin K do not affect anticoagulant activity No experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) No scientific rationale for reversal No experience with systemic hemostatics (desmopressin and aprotinin) Use of procoagulant reversal agents such as prothrombin complex concentrate, activated prothrombin complex concentrate, or rfviia may be considered but have not been evaluated in clinical studies Activated oral charcoal reduces adsorption, thereby lowering apixaban plasma concentration Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; December 2012.

19 Managing Bleeding in Patients Receiving Dabigatran Dabigatran Inhibits last step in coagulation cascade; any agent that stimulates this cascade or replaces coagulation factors proximal to thrombin will not compensate for the profound terminal hemostatic defect 1 Activated charcoal or gastric lavage early after ingestion 1 Completely adsorbs lipophilic drug in solution 1 PCC not known to mitigate anticoagulant effect 1 Consider activated PCC (very high doses) 2 rfviia recommended in PI for life-threatening bleeding 1,2 Triggers thrombin generation Has not been shown to reverse bleeding complications Has a very short half-life Expensive Associated with otherwise avoidable thromboembolism Acute hemodialysis for extreme cases 1 Only 35% of dabigatran protein bound 6 hours of dialysis decreased thrombin clotting time from 150 to 68 seconds 1. Schulman S, et al. Blood. 2012;119: ; 2. Ageno W, et al. Chest. 2012;141(suppl 1):e44s-e88s.

20 Managing Bleeding in Patients Receiving Rivaroxaban May be effective: Rivaroxaban All measurable anticoagulant effect reversed by 4-factor PCC in healthy male volunteers 1 can use 50 IU/kg in the case of acute major bleeding 3-factor PCC still available in US 1 Not dialyzable because highly protein bound (92%-95%) 2 Activated oral charcoal may be considered as it reduces absorption 3 1. Schulman S, et al. Blood. 2012;119: ; 2. Ageno W, et al. Chest. 2012;141(suppl 1):e44s-e88s; 3. Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; Nov

21 Managing NOAC-related bleeding Practical Considerations Intracranial bleeds are significantly less common with NOACs than with warfarin The BEST strategy to treat bleeding is to prevent it Primum non nocere Half-lives of NOACs are short if the patient has normal renal function Appropriate patient selection PCCs should be used when clinically appropriate. The risk benefit of thrombosis must be considered Dialysis is indicated for severe bleeding with dabigatran Camm JA, et al. Eur Heart J. 2012;33: ; Schulman S, et al. Blood. 2012;119:

22 Summary NOACs are safer and more predictable than warfarin Shorter half-life Significantly lower rates of ICH than warfarin Cannot be readily assessed/monitored No oral anticoagulant-based major bleeding event can simply be reversed

48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.

48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact. 48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants

More information

Speaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014

Speaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014 Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,

More information

New anticoagulants: Monitoring or not Monitoring? Not Monitoring

New anticoagulants: Monitoring or not Monitoring? Not Monitoring The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and

More information

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will

More information

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients

More information

Disclosure. Warfarin

Disclosure. Warfarin Disclosure No conflicts of interest to disclose Reversal Strategies for Novel Oral Anticoagulants Noelle de Leon, PharmD, BCPS Critical Care Pharmacist, Department of Pharmaceutical Services Assistant

More information

Comparison between New Oral Anticoagulants and Warfarin

Comparison between New Oral Anticoagulants and Warfarin Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several

More information

NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM

NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin

More information

New Oral Anticoagulants

New Oral Anticoagulants Laboratory Monitoring of New Oral Anticoagulants.....What you need to know Rita Selby MD Medical Director, Coagulation Laboratories Uniersity Health Network & Sunnybrook HSC Uniersity of Toronto The 15

More information

Anticoagulation and Reversal

Anticoagulation and Reversal Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,

More information

5/21/2012. Perioperative Use Issues. On admission: During hospitalization:

5/21/2012. Perioperative Use Issues. On admission: During hospitalization: Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:

More information

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis

More information

Disclosures. New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century

Disclosures. New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University

More information

DABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN

DABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)

More information

Reversing the New Anticoagulants

Reversing the New Anticoagulants Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today

More information

The management of cerebral hemorrhagic complications during anticoagulant therapy

The management of cerebral hemorrhagic complications during anticoagulant therapy The management of cerebral hemorrhagic complications during anticoagulant therapy Maurizio Paciaroni Stroke Unit Division of Cardiovascular Medicine University of Perugia - Italy Perugia Stroke Registry

More information

Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師

Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367

More information

Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)

Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Dr. Art Szkotak artur.szkotak@albertahealthservices.ca University of Alberta Hospital Edmonton, AB NOACs Direct Thrombin Inhibitors (DTI):

More information

Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services

Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug

More information

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000

More information

To assist clinicians in the management of minor, major, and/or life-threatening bleeding in patients receiving new oral anticoagulants (NOACs).

To assist clinicians in the management of minor, major, and/or life-threatening bleeding in patients receiving new oral anticoagulants (NOACs). MANAGEMENT OF BLEEDING IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To assist clinicians

More information

USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)

USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:

More information

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015 Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents

More information

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy ~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:

More information

Reversal of Anticoagulants at UCDMC

Reversal of Anticoagulants at UCDMC Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant

More information

Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare

Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:

More information

Current and Emerging Therapies for Perioperative Anticoagulation Reversal

Current and Emerging Therapies for Perioperative Anticoagulation Reversal Current and Emerging Therapies for Perioperative Anticoagulation Reversal Eric Johnson, PharmD, BCCCP Critical Care Pharmacist- Perioperative Services Objectives Detail the approach to perioperative anticoagulation

More information

Novel Anticoagulants

Novel Anticoagulants Novel Anticoagulants Mark T. Reding, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation Director, Center for Bleeding and Clotting Disorders University of Minnesota

More information

MANAGING BLEEDING IN THE

MANAGING BLEEDING IN THE MANAGING BLEEDING IN THE SETTING OF NEW ANTICOAGULANTS: HOW DO OLD METHODS MEASURE UP? Michelle Zeller MD Clinical Hematology Fellow November 5th, 2011 A FRIDAY NIGHT ON-CALL WITH DR. B. LUD Very keen

More information

LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options

LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow

More information

Now We Got Bad Blood: New Anticoagulant Reversal

Now We Got Bad Blood: New Anticoagulant Reversal Now We Got Bad Blood: New Anticoagulant Reversal Kellie Rodriguez, PharmD, BCPS PGY2 Emergency Medicine Pharmacy Resident UF Health Jacksonville January 2016 Objectives 1. Review current treatment strategies

More information

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment

More information

New Anticoagulation Agents and Their Reversal Agents. Objectives. Background 12/21/2015

New Anticoagulation Agents and Their Reversal Agents. Objectives. Background 12/21/2015 New Anticoagulation Agents and Their Reversal Agents Jay Hazelcorn, Pharm.D. PGY-1 Pharmacy Resident Broward Health Medical Center Objectives Review the pharmacology, indications, and place in therapy

More information

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November

More information

The Anticoagulated Patient A Hematologist s Perspective

The Anticoagulated Patient A Hematologist s Perspective The Anticoagulated Patient A Hematologist s Perspective Deborah M. Siegal MD MSc FRCPC Clinical Scholar Division of Hematology and Thromboembolism Thrombosis Canada Research Fellow McMaster University

More information

DISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose

DISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose DISCLOSURES CATEGORY Employment Research support Scientific advisory board Consultancy Speakers bureau Major stockholder Patents Honoraria Travel support Other CONFLICT No conflict of interest to disclose

More information

New Anticoagulants: When and Why Should I Use Them? Disclosures

New Anticoagulants: When and Why Should I Use Them? Disclosures Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia

More information

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in

More information

3/17/2014. No conflicts of interest to report

3/17/2014. No conflicts of interest to report No conflicts of interest to report Patrick M. Lewis, Pharm.D., BCPS, CACP Lahey Hospital & Medical Center Burlington, MA April 1 st 2014 Parts of this presentation discuss off-label use of reversal agents.

More information

Impact of new (direct) oral anticoagulants in patient blood management

Impact of new (direct) oral anticoagulants in patient blood management Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,

More information

Traditional anticoagulants

Traditional anticoagulants TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

New Oral Anticoagulants. July 2012

New Oral Anticoagulants. July 2012 New Oral Anticoagulants July 2012 Objectives Review coagulation cascade and previous treatment options for anticoagulation Understand points of interaction within coagulation cascade and new oral agents

More information

Anticoagulation Essentials! Parenteral and Oral!

Anticoagulation Essentials! Parenteral and Oral! Anticoagulation Essentials! Parenteral and Oral! Anti-Xa and Anti-IIa! Parenteral Anticoagulants! Heparin family (indirect anti-xa and anti-iia):! UFH! LMWH (enoxaparin, fondaparinux)! Direct thrombin

More information

The Brave New (Anticoagulant) World

The Brave New (Anticoagulant) World The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA

More information

Reversal of Old and New Antithrombotic Drugs. Mike Makris

Reversal of Old and New Antithrombotic Drugs. Mike Makris Reversal of Old and New Antithrombotic Drugs Mike Makris BCSH guidelines Guidelines on oral anticoagulation with warfarin fourth edition 1 Guideline on the urgent or emergency reversal of antithrombotic

More information

The author has no disclosures

The author has no disclosures Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author

More information

New Anticoagulants: What to Use What to Avoid

New Anticoagulants: What to Use What to Avoid New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA

More information

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012 New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk

More information

De effecten van Cofact op Rivaroxaban plasma in trombine generatie assays

De effecten van Cofact op Rivaroxaban plasma in trombine generatie assays De effecten van Cofact op Rivaroxaban plasma in trombine generatie assays In vitro assessment, using thrombin generation, of the applicability of Prothrombin Complex Concentrate as an antidote for Rivaroxaban

More information

What to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille

What to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille What to do in case of hemorragia with NOAC? L Camoin Jau Service d Hématologie APHM Marseille Disclosure Boehringer Bayer Daishi Sanofi BMS Pharmacodynamic and kinetic properties of new oral anticoagulants.

More information

Objectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants

Objectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence

More information

New Oral Anticoagulant Drugs What monitoring if any is required?

New Oral Anticoagulant Drugs What monitoring if any is required? New Oral Anticoagulant Drugs What monitoring if any is required? Michelle Williamson Supervising Scientist High Throughput Haematology Pathology Queensland PAH Laboratory Overview Background What new oral

More information

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,

More information

CHALLENGES AND OPPORTUNITIES IN CLINICAL USE OF THE NEW ORAL ANTICOAGULANTS. Amy Giovino, PharmD Formulary Coordinator Sarasota Memorial Hospital

CHALLENGES AND OPPORTUNITIES IN CLINICAL USE OF THE NEW ORAL ANTICOAGULANTS. Amy Giovino, PharmD Formulary Coordinator Sarasota Memorial Hospital CHALLENGES AND OPPORTUNITIES IN CLINICAL USE OF THE NEW ORAL ANTICOAGULANTS Amy Giovino, PharmD Formulary Coordinator Sarasota Memorial Hospital 1 2 Disclosure I do not have a vested interest in or affiliation

More information

DOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant

DOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X

More information

1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using

1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI

More information

Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012

Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present

More information

3/3/2015. Patrick Cobb, MD, FACP March 2015

3/3/2015. Patrick Cobb, MD, FACP March 2015 Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict

More information

Disclosures. Objective (NRHS) Self Assessment #2

Disclosures. Objective (NRHS) Self Assessment #2 Development and Implementation of a Protocol for Reversing the Effects of Anticoagulants for Use in a Community Hospital Samantha Sepulveda, Pharm.D. PGY1 Pharmacy Resident Norman Regional Health System

More information

Dabigatran (Pradaxa) Guidelines

Dabigatran (Pradaxa) Guidelines Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without

More information

New Oral AntiCoagulants (NOAC) in 2015

New Oral AntiCoagulants (NOAC) in 2015 New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research

More information

Management for Deep Vein Thrombosis and New Agents

Management for Deep Vein Thrombosis and New Agents Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular

More information

Cardiology Update 2014

Cardiology Update 2014 Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The

More information

EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013

EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013 EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults February, 2013 1 Quick Index To Reversal Recommendations Anti-Platelet Medications Page P2Y12

More information

Anticoagulants. Denver Health April 12, 2011

Anticoagulants. Denver Health April 12, 2011 New Oral Anticoagulants Rebecca Hanratty, MD Denver Health April 12, 2011 Overview Why we need alternatives to warfarin Review of the 3 new oral anticoagulants Results from major trials: Thromboprophylaxis

More information

New Oral Anticoagulants

New Oral Anticoagulants Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.

More information

QUICK REFERENCE. Mary Cushman 1 Wendy Lim 2 Neil A Zakai 1. University of Vermont 2. McMaster University

QUICK REFERENCE. Mary Cushman 1 Wendy Lim 2 Neil A Zakai 1. University of Vermont 2. McMaster University QUICK REFERENCE Clinical Practice Guide on Antithrombotic Drug Dosing and Management of Antithrombotic Drug- Associated Bleeding Complications in Adults February 2014* Mary Cushman 1 Wendy Lim 2 Neil A

More information

Monitoring of new oral anticoagulants

Monitoring of new oral anticoagulants Monitoring of new oral anticoagulants Jonathan Douxfils, Bernard Chatelain September 27th, 2012 1 Content Introduction Monitoring of NOACs Why? Dabigatran etexilate PD properties PK properties Rivaroxaban

More information

NON-VITAMIN K ORAL ANTICOAGULANT REVERSAL

NON-VITAMIN K ORAL ANTICOAGULANT REVERSAL DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care

More information

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

Blood products and pharmaceutical emergencies

Blood products and pharmaceutical emergencies Blood products and pharmaceutical emergencies Kasey L. Bucher PharmD, BCPS Clinical Specialist, Emergency Medicine Mercy Health Saint Mary s September 12, 2013 Disclosures None significancemagazine.com

More information

Disclosures. I have served as an advisory board member, consultant, speaker, and / or received research funding from: Sanofi-Aventis

Disclosures. I have served as an advisory board member, consultant, speaker, and / or received research funding from: Sanofi-Aventis TSOACs: Glee Lenoir, Pharm D. Pharmacy Clinical Coordinator The Medical Center Nursing Conference March 2015 Disclosures I have served as an advisory board member, consultant, speaker, and / or received

More information

Anticoagulant Treatment for Deep Venous Thrombosis Direct Oral Anticoagulants (NOACs)

Anticoagulant Treatment for Deep Venous Thrombosis Direct Oral Anticoagulants (NOACs) Anticoagulant Treatment for Deep Venous Thrombosis Direct Oral Anticoagulants (NOACs) Prof. P. HAINAUT Médecine Interne - Maladie Thromboembolique Cliniques Univ. Saint Luc - UCL Background Direct Oral

More information

New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther

New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,

More information

NON-VITAMIN K ORAL ANTICOAGULANT REVERSAL

NON-VITAMIN K ORAL ANTICOAGULANT REVERSAL DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care

More information

Adherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015

Adherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015 Adherence to NOACs Patricia van den Bemt EAHP Hamburg 2015 Disclosure Unrestricted research grants from Glaxo-SmithKline Boehringer Ingelheim Daiichi Sankyo Bayer Pfizer For research on medication safety

More information

Troubled by warfarin s narrow therapeutic index, numerous

Troubled by warfarin s narrow therapeutic index, numerous Jeremy W. Vandiver, PharmD, BCPS; Douglas Faulkner, MD; Michael Erlandson, MD; Mary Onysko, PharmD, BCPS University of Wyoming School of Pharmacy, Laramie (Drs. Vandiver and Onysko); Hampden Medical Group,

More information

Novel OAC s : How should we use them?

Novel OAC s : How should we use them? Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker

More information

Making Sense of the Newer Anticoagulants

Making Sense of the Newer Anticoagulants Making Sense of the Newer Anticoagulants Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center I M FROM ARIZONA! DISCLOSURES No relevant

More information

Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.

Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D. Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical

More information

Critical Bleeding Reversal Protocol

Critical Bleeding Reversal Protocol Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy

More information

No more rat poison? New oral anticoagulants and perioperative considerations

No more rat poison? New oral anticoagulants and perioperative considerations 1 No more rat poison? New oral anticoagulants and perioperative considerations Jerrold H. Levy, MD, FAHA, FCCM Professor Department of Anesthesiology/Critical Care Duke University School of Medicine Durham,

More information

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012 The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received

More information

New Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D.

New Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D. New Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D. Introduction Since the 1950 s, the only orally available anticoagulant has been the vitamin K antagonist

More information

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71 Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.

More information

Dr Gordon Royle Haematologist, Middlemore Hospital

Dr Gordon Royle Haematologist, Middlemore Hospital The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary

More information

Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation

Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants

More information

PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent Primary Care Center

PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent Primary Care Center Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent

More information

The speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.

The speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products. Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives

More information

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,

More information

A New Era of Oral Anticoagulant Therapy

A New Era of Oral Anticoagulant Therapy A New Era of Oral Anticoagulant Therapy Jack Ansell, M.D. Lenox Hill Hospital June 16, 2011 Disclosures: Consultant for Ortho McNeil; Bristol Myers Squibb; Boehringer Ingelheim; Daiichi Anticoagulants

More information

Disclosure. Outline. Objectives. I have no actual or potential conflict of interest in relation to this presentation.

Disclosure. Outline. Objectives. I have no actual or potential conflict of interest in relation to this presentation. Disclosure I have no actual or potential conflict of interest in relation to this presentation. Sarah Lombardo, MD., MSc. General Surgery, University of Utah September 9, 2015 Objectives Outline Recognize

More information

Breadth of indications matters One drug for multiple indications

Breadth of indications matters One drug for multiple indications Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:

More information

Management of atrial fibrillation. Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD

Management of atrial fibrillation. Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD Management of atrial fibrillation Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD Antithrombotic therapy in atrial fibrillation Satchana Pumprueg, MD AF has serious consequences Independent

More information

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime

More information

Comparative Anticoagulation

Comparative Anticoagulation Comparative Anticoagulation Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center Pharmacotherapy

More information

NOACs 2013: Evolving Anticoagulation Options. Erik Yeo MD University Health Network University of Toronto

NOACs 2013: Evolving Anticoagulation Options. Erik Yeo MD University Health Network University of Toronto NOACs 2013: Evolving Anticoagulation Options Erik Yeo MD University Health Network University of Toronto Objectives Clinical overview the new oral anticoagulants and their management issues Rivaroxaban

More information

Practical Aspects of Novel Oral Anticoagulants (NOACs)

Practical Aspects of Novel Oral Anticoagulants (NOACs) Practical Aspects of Novel Oral Anticoagulants (NOACs) Edith Nutescu, Pharm.D., FCCP Clinical Professor University of Illinois at Chicago College of Pharmacy University of Illinois Hospital & Health Sciences

More information

Novel OACs: How should we use them?"

Novel OACs: How should we use them? Novel OACs: How should we use them?" Iqwal Mangat, MD FRCPC" Director, Arrhythmia Service, St. Michaelʼs Hospital" Assistant Professor of Medicine, University of Toronto" Presenter Disclosure Dr. Iqwal

More information